Eli Lilly's $650 million deal with Juvena Therapeutics focuses on using AI-enabled screening platforms to identify novel candidates boosting muscle health and regeneration, aiming to complement Lilly's pipeline amidst growing interest in muscle-related therapies, marking a strong industry move toward innovative biologics development.